Medline, Inc. successfully completed a $7.2 billion initial public offering, aiming to reduce debt and strengthen its market position in the healthcare sector.

Information on the Target

Medline, Inc. is a prominent provider of medical-surgical products and supply chain solutions, catering to various healthcare settings. Headquartered in Northfield, Illinois, the company employs over 43,000 individuals and operates in more than 100 countries, positioning itself as a leader in the healthcare industry. Medline's extensive product portfolio, strong supply chain, and innovative clinical solutions enable healthcare providers to enhance their clinical, financial, and operational outcomes.

The recent upsized initial public offering (IPO) consisted of 248,439,654 shares of Class A common stock, priced at $29.00 per share, resulting in gross proceeds of approximately $7.2 billion. The proceeds will primarily be utilized to reduce existing debt and facilitate the redemption of equity interests held by pre-IPO stakeholders.

Industry Overview in the Target’s Specific Country

The healthcare sector in North America has seen significant growth driven by continuous advancements in medical technology and an increase in healthcare spending. The demand for medical supplies and equipment is anticipated to r

View Source

Similar Deals

Blackstone, TPG, and other minorities (ADIA, GIC) Hologic, Inc.

2025

Public-to-Private (P2P) Medical Diagnostic & Testing Equipment United States of America
Single Institutional Investor Glucotrack, Inc.

2025

Public-to-Private (P2P) Medical Devices & Implants United States of America
Novartis Regulus Therapeutics

2025

Public-to-Private (P2P) Bio Therapeutic Drugs United States of America
Crescent Biopharma, Inc. GlycoMimetics, Inc.

2025

Public-to-Private (P2P) Bio Therapeutic Drugs United States of America
MapLight Therapeutics MapLight Therapeutics

2025

Public-to-Private (P2P) Bio Therapeutic Drugs United States of America
Abbott Laboratories Senseonics Holdings, Inc.

2025

Public-to-Private (P2P) In-Vivo Diagnostic & Testing Substances United States of America

Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LP

invested in

Medline, Inc.

in 2025

in a Public-to-Private (P2P) deal

Disclosed details

Transaction Size: $7,200M

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert